Tirzepatide in Advanced CKD (eGFR <30)
Type 2 diabetes is the leading cause of chronic kidney disease (CKD), and approximately 5–10% of T2D adults have advanced CKD (eGFR <30 mL/min/1.73m² — CKD G4 or G5). These patients carry the highest cardiovascular and all-cause mortality risk in T2D, yet they are systematically excluded from clinical trials of new glucose-lowering therapies because trial safety requirements and PK variability make inclusion challenging. Tirzepatide’s SURPASS programme follows this pattern: all SURPASS trials excluded patients with eGFR <30.
What SURPASS-4 does show (CKD G3+, eGFR 30–59): A post-hoc analysis of SURPASS-4 (vs insulin glargine, high CV risk T2D, n=2002, 104 weeks) demonstrated that tirzepatide preserved eGFR better than glargine in CKD G3+ patients — between-group difference 3.7 mL/min/1.73m²/year (95% CI 2.4–5.1). This preservation was more pronounced in lower eGFR subgroups within G3 and was seen even in normoalbuminuric patients. Tirzepatide also nearly halved the risk of a pre-specified composite kidney endpoint (eGFR decline ≥40%, renal death, kidney failure, or new-onset macroalbuminuria) vs glargine. Importantly, this is a post-hoc analysis, not a primary kidney outcome trial.
Ontology Tirzepatide in Advanced CKD [relates] Tirzepatide Tirzepatide in Advanced CKD [relates] KDIGO 2022 CKD Diabetes Guideline Tirzepatide in Advanced CKD [part-of] Type 2 Diabetes
The early eGFR dip (important misinterpretation risk): Tirzepatide causes a transient eGFR decline (creatinine-based) at approximately 12 weeks. This pattern mirrors what is seen with SGLT2 inhibitors and RAAS agents — it is a haemodynamic effect (reduced glomerular hyperfiltration) and a reflection of reduced muscle mass, not nephrotoxicity. Critically, this dip is NOT seen when eGFR is estimated using cystatin C rather than creatinine, confirming the creatinine-based dip is largely a confound from weight loss and reduced muscle mass. Clinicians using creatinine-based eGFR monitoring in T2D patients starting tirzepatide should not interpret a small early eGFR decline as evidence of renal damage without cystatin C confirmation.
Ontology Tirzepatide in Advanced CKD [relates] SGLT2 Inhibitors Tirzepatide in Advanced CKD [relates] Side Effects Profile
FDA label and pharmacokinetics: The FDA Mounjaro prescribing information specifies no dose adjustment is required for renal impairment at any severity, including severe CKD (eGFR <30). Tirzepatide is not renally cleared — it is a large peptide eliminated by proteolysis and albumin-binding-mediated catabolism, similar to endogenous GIP and GLP-1. This makes it pharmacokinetically distinct from metformin (contraindicated in eGFR <30) or SGLT2 inhibitors (losing efficacy below eGFR ~45). The absence of dose adjustment requirement does not mean absence of safety concerns — GI side effects causing dehydration are a practical risk in patients with limited fluid reserve capacity, particularly anuric dialysis patients.
TREASURE-CKD trial (NCT05536804): Eli Lilly’s ongoing mechanistic trial of tirzepatide in participants with overweight or obesity and CKD, with or without T2D. This trial is designed to assess tirzepatide’s effects on kidney function in a CKD-enriched population, likely including lower eGFR ranges. Results will be the first prospective data on tirzepatide in patients closer to eGFR <30. No results published as of April 2026.
Ontology Tirzepatide in Advanced CKD [relates] TREASURE-CKD
What Is Known vs Unknown
| Aspect | Status |
|---|---|
| eGFR G3 (30–59) safety | Confirmed in SURPASS-4 post-hoc — eGFR preserved vs glargine |
| eGFR G4-G5 (<30) trial data | Not available — excluded from all SURPASS trials |
| Dose adjustment needed? | None required (FDA label — not renally cleared) |
| Early eGFR dip | Present (creatinine-based) — haemodynamic, not nephrotoxic |
| Dialysis patients | No data |
| TREASURE-CKD | Ongoing — results pending |
Practical Interpretation for Clinicians
- For eGFR 30–59 (CKD G3): Reassuring post-hoc data from SURPASS-4; can be used without dose adjustment; monitor for haemodynamic eGFR dip
- For eGFR <30 (CKD G4-G5): No trial data; FDA label permits use; clinical judgment required; monitor hydration if GI side effects occur
- Key caveat: This is the most important population gap in the tirzepatide evidence base for T2D — the patients with highest mortality risk are those with the least evidence
Connections
- Tirzepatide — relates (evidence gap for advanced CKD)
- KDIGO 2022 CKD Diabetes Guideline — relates (guidance stops at eGFR 20 for metformin; GLP-1 RA recommended but trial data thin for eGFR <30)
- SGLT2 Inhibitors — contrasts (DAPA-CKD/CREDENCE included eGFR down to 25-30; more CKD-specific evidence)